Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer.
Frank KJ, Mulero-Sánchez A, Berninger A, Ruiz-Cañas L, Bosma A, Görgülü K, Wu N, Diakopoulos KN, Kaya-Aksoy E, Ruess DA, Kabacaoğlu D, Schmidt F, Kohlmann L, van Tellingen O, Thijssen B, van de Ven M, Proost N, Kossatz S, Weber WA, Sainz B Jr, Bernards R, Algül H, Lesina M, Mainardi S. Frank KJ, et al. Among authors: mainardi s. Cell Rep Med. 2022 Nov 15;3(11):100815. doi: 10.1016/j.xcrm.2022.100815. Cell Rep Med. 2022. PMID: 36384095 Free PMC article.
A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes.
Careccia S, Mainardi S, Pelosi A, Gurtner A, Diverio D, Riccioni R, Testa U, Pelosi E, Piaggio G, Sacchi A, Lavorgna S, Lo-Coco F, Blandino G, Levrero M, Rizzo MG. Careccia S, et al. Among authors: mainardi s. Oncogene. 2009 Nov 12;28(45):4034-40. doi: 10.1038/onc.2009.255. Epub 2009 Sep 14. Oncogene. 2009. PMID: 19749800
A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility.
Vecchione L, Gambino V, Raaijmakers J, Schlicker A, Fumagalli A, Russo M, Villanueva A, Beerling E, Bartolini A, Mollevi DG, El-Murr N, Chiron M, Calvet L, Nicolazzi C, Combeau C, Henry C, Simon IM, Tian S, in 't Veld S, D'ario G, Mainardi S, Beijersbergen RL, Lieftink C, Linn S, Rumpf-Kienzl C, Delorenzi M, Wessels L, Salazar R, Di Nicolantonio F, Bardelli A, van Rheenen J, Medema RH, Tejpar S, Bernards R. Vecchione L, et al. Among authors: mainardi s. Cell. 2016 Apr 7;165(2):317-30. doi: 10.1016/j.cell.2016.02.059. Cell. 2016. PMID: 27058664 Free article.
SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.
Mainardi S, Mulero-Sánchez A, Prahallad A, Germano G, Bosma A, Krimpenfort P, Lieftink C, Steinberg JD, de Wit N, Gonçalves-Ribeiro S, Nadal E, Bardelli A, Villanueva A, Bernards R. Mainardi S, et al. Nat Med. 2018 Jul;24(7):961-967. doi: 10.1038/s41591-018-0023-9. Epub 2018 May 28. Nat Med. 2018. PMID: 29808006 Free article.
A System-wide Approach to Monitor Responses to Synergistic BRAF and EGFR Inhibition in Colorectal Cancer Cells.
Ressa A, Bosdriesz E, de Ligt J, Mainardi S, Maddalo G, Prahallad A, Jager M, de la Fonteijne L, Fitzpatrick M, Groten S, Altelaar AFM, Bernards R, Cuppen E, Wessels L, Heck AJR. Ressa A, et al. Among authors: mainardi s. Mol Cell Proteomics. 2018 Oct;17(10):1892-1908. doi: 10.1074/mcp.RA117.000486. Epub 2018 Jul 3. Mol Cell Proteomics. 2018. PMID: 29970458 Free PMC article.
Inducing and exploiting vulnerabilities for the treatment of liver cancer.
Wang C, Vegna S, Jin H, Benedict B, Lieftink C, Ramirez C, de Oliveira RL, Morris B, Gadiot J, Wang W, du Chatinier A, Wang L, Gao D, Evers B, Jin G, Xue Z, Schepers A, Jochems F, Sanchez AM, Mainardi S, Te Riele H, Beijersbergen RL, Qin W, Akkari L, Bernards R. Wang C, et al. Among authors: mainardi s. Nature. 2019 Oct;574(7777):268-272. doi: 10.1038/s41586-019-1607-3. Epub 2019 Oct 2. Nature. 2019. PMID: 31578521 Free PMC article.
RASON, a new player in cancer's Premier League.
Mainardi S, Bernards R. Mainardi S, et al. Cell Res. 2023 Jan;33(1):1-2. doi: 10.1038/s41422-022-00750-7. Cell Res. 2023. PMID: 36588118 Free PMC article. No abstract available.
Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma.
Mulero-Sánchez A, Ramirez CFA, du Chatinier A, Wang H, Koomen SJI, Song JY, de Groot MHP, Lieftink C, Bosma A, Burylo A, van Tellingen O, Beijersbergen RL, Wang C, Akkari L, Bernards R, Mainardi S. Mulero-Sánchez A, et al. Among authors: mainardi s. Mol Oncol. 2023 Jun;17(6):964-980. doi: 10.1002/1878-0261.13377. Epub 2023 Feb 9. Mol Oncol. 2023. PMID: 36650715 Free PMC article.
29 results